FluBHPVE6E7 immunotherapy for HPV16-positive oropharyngeal cancer
Part of Cancer clinical trials.
This trial tests a new immunotherapy called FluBHPVE6E7 for people with HPV16-positive oropharyngeal cancer that has not spread to distant parts of the body. The treatment is given directly into the tumor to help the immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- You have been diagnosed with oropharyngeal cancer that is p16-positive and HPV16-positive
- Your cancer is locally advanced (stages like T2N2-3, T3N0-3, or T4N0-3) and has not spread to distant organs
- You are in good physical condition (Karnofsky score 70-100, ECOG 0 or 1)
- You can have a biopsy and the treatment injection directly into your tumor
- You agree to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a less intense treatment approach for people with HPV-positive oropharyngeal cancer. It uses surgery first, followed by fewer or lower doses of radiation and chemotherapy, aiming to reduce side effects while keeping treatment effective.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests whether radiation or chemoradiation works well for HPV-positive throat cancer. It may be an option if you have this type of cancer and are getting or have already had surgery.
This trial tests a therapeutic vaccine for people with HPV16-positive oropharyngeal cancer who have finished curative treatment and are free of disease. The vaccine aims to help the immune system prevent the cancer from coming back.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Hear when a new Oropharyngeal Squamous Cell Carcinoma (SCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.